세계의 이식형 의료기기 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 생체재료별, 최종용도별, 지역별, 부문 예측(2024-2030년)

Implantable Medical Devices Market Trends

The global implantable medical devices market size was estimated at USD 91.5 billion in 2023 and is projected to grow at a CAGR of 6.1 % from 2024 to 2030, owing to the advancements in technology, increasing prevalence of chronic diseases, and growing demand for minimally invasive surgical procedures. Advancements in surgical techniques, particularly minimally invasive procedures, have expanded the application of implantable medical devices. For instance, in January 2024, Accelus, a US-based medical technology company, introduced a modular-cortical system for spinal implant surgeries. The system allows surgeons to place screw shanks early and customize the construct. The system is available in open and cortical sets, catering to different surgical approaches.

Technological innovation plays a pivotal role in driving the market growth. Advances in materials science, miniaturization, biocompatibility, and sensor technology have revolutionized the design and functionality of implantable devices. For instance, the development of advanced biomaterials such as titanium alloys and bioresorbable polymers has enhanced the durability, biocompatibility, and integration of implants within the body. These materials reduce the risk of rejection, promote tissue regeneration, and improve long-term outcomes for patients.

Moreover, sensor technology and wireless connectivity have enabled implantable devices to collect real-time data on physiological parameters and transmit this information to healthcare providers remotely. This capability supports remote monitoring, early detection of complications, and timely intervention. For example, implantable cardiac monitors can continuously monitor heart rhythms and detect arrhythmias, allowing physicians to intervene promptly and prevent adverse cardiac events.

The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and orthopedic conditions drives the demand for implantable medical devices. According to the World Health Organization (WHO), around 422 million people worldwide, primarily in low- and middle-income countries, are affected by diabetes, which causes 1.5 million deaths annually, with the number of cases and prevalence increasing steadily in recent decades.

Implantable medical devices play a critical role in managing chronic conditions, improving patient mobility, and enhancing quality of life. For instance, orthopedic implants such as hip and knee replacements restore joint function and alleviate pain in patients with osteoarthritis, enabling them to maintain an active lifestyle. In addition, implantable devices are increasingly used in the treatment of neurological disorders such as Parkinson's disease and epilepsy. According to Parkinson's Foundation article published in 2022-23, nearly 90,000 people in the U.S. are diagnosed yearly for Parkinson condition. Moreover, around 1 million people in the country are living with the condition. Neurostimulation devices deliver electrical impulses to targeted areas of the brain or nerves, reducing symptoms such as tremors or seizures and improving patients' daily functioning and quality of life.

Global Implantable Medical Devices Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global implantable medical devices market report based on product, biomaterial, end use, and regions:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Cardiovascular Implants
• Orthopedic Implants
• Ophthalmology Implants
• Dental Implants
• Aesthetic Implants
• Neurology Implants
• Biomaterial Outlook (Revenue, USD Million, 2018 - 2030)
• Ceramic
• Metallic
• Polymers
• Natural
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Outpatient Facilities
• Specialty Clinics & Centers
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Biomaterial
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Biomaterial Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Implantable Medical Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing In Prevalence Of Chronic Diseases
    • 3.2.1.2. Technological Advancement
    • 3.2.1.3. Growing Demand For Minimally Invasive Surgical Procedures
  • 3.2.2. Market Restraint Analysis
• 3.3. Implantable Medical Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
• 3.4. Pricing Analysis, at Regional Level
  • 3.4.1. North America
  • 3.4.2. Europe
  • 3.4.3. Asia Pacific
  • 3.4.4. Latin America
  • 3.4.5. MEA

Chapter 4. Implantable Medical Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Implantable Medical Devices Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 4.2.1. Cardiovascular Implants
    • 4.2.1.1. Cardiovascular Implants Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.2. Orthopedic Implants
    • 4.2.2.1. Orthopedic Implants Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.3. Ophthalmology Implants
    • 4.2.3.1. Ophthalmology Implants Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.4. Dental Implants
    • 4.2.4.1. Dental Implants Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.5. Aesthetic Implants
    • 4.2.5.1. Aesthetic Implants Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.6. Neurology Implants
    • 4.2.6.1. Neurology Implants Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Implantable Medical Devices Market: Biomaterial Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Implantable Medical Devices Market: Biomaterial Movement Analysis, USD Million, 2023 & 2030
  • 5.2.1. Ceramic
    • 5.2.1.1. Ceramic Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.2. Metallic
    • 5.2.2.1. Metallic Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.3. Polymers
    • 5.2.3.1. Polymers Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.4. Natural
    • 5.2.4.1. Natural Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Implantable Medical Devices Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Implantable Medical Devices Market: End Use Movement Analysis, USD Million, 2023 & 2030
  • 6.2.1. Hospitals
    • 6.2.1.1. Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.2.2. Outpatient Facilities
    • 6.2.2.1. Outpatient Facilities Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.2.3. Specialty Clinics & Centers & Centers
    • 6.2.3.1. Specialty Clinics & Centers & Centers Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Implantable Medical Devices Market: Regional Estimates & Trend Analysis, by Product, Biomaterial, and End Use

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2023
  • 8.3.2. Medtronic
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product Type benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Abbott Laboratories
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product Type benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Johnson and Jhonson
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Boston Scientific Corporation
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Smith & Nephew plc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Stryker
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Cochlear Limited
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Integra LifeSciences
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. LivaNova PLC
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Biotronik SE and Co. KG
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product Type benchmarking
    • 8.3.11.4. Strategic initiatives